Authors: Palumbo, A Giaccone, L Bertola, A Pregno, P Bringhen, S Rus, C Triolo, S Gallo, E Pileri, A Boccadoro, M

Citation: A. Palumbo et al., Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma, HAEMATOLOG, 86(4), 2001, pp. 399-403

Authors: Palumbo, A Triolo, S Baldini, L Callea, V Capaldi, A De Stefano, V Grasso, M Liberati, M Lotesoriere, C Marceno, R Marmont, F Musto, P Petrucci, MT Spriano, M Pileri, A Boccadoro, M

Citation: A. Palumbo et al., Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients, HAEMATOLOG, 85(5), 2000, pp. 508-513

Authors: Boccadoro, M Omede, P Dominietto, A Palumbo, A Bringhen, S Giaretta, F Ortolano, B Triolo, S Pileri, A

Citation: M. Boccadoro et al., Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support, BONE MAR TR, 25(1), 2000, pp. 25-29

Authors: Boccadoro, M Tarella, C Palumbo, A Argentino, C Triolo, S Dominietto, A Callea, V Lauta, VM Molica, S Musto, P Marmont, F Gianni, AM Pileri, A

Citation: M. Boccadoro et al., An analysis of which subgroups of multiple myeloma patients, divided according to beta(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy, HAEMATOLOG, 84(10), 1999, pp. 905-910

Authors: Palumbo, A Triolo, S Argentino, C Bringhen, S Dominietto, A Rus, C Omede, P Tarella, C Pileri, A Boccadoro, M

Citation: A. Palumbo et al., Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients, BLOOD, 94(4), 1999, pp. 1248-1253